Drug Analysis: Dupixent

  • ID: 4489119
  • Drug Pipelines
  • 27 pages
  • Datamonitor Healthcare
1 of 4
Drug Overview

Dupixent (dupilumab; Regeneron/Sanofi) is an injectable monoclonal antibody directed against the interleukin (IL)-4 receptor alpha subunit, which blocks signaling from both IL-4 and IL-13. This is a novel mechanism of action for the treatment of severe asthma, with the majority of marketed biologics targeting IL-5.
Note: Product cover images may vary from those shown
2 of 4
1 Product Profiles
  • Dupixent: Asthma
  • Dupixent: Atopic dermatitis
List of Figures
Figure 53: Trelegy Ellipta for asthma - SWOT analysis
Figure 54: The author’s drug assessment summary of Trelegy Ellipta in asthma
Figure 55: The author’s drug assessment summary of Trelegy Ellipta in asthma
Figure 56: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 56: Xolair for asthma - SWOT analysis
Figure 6: The author’s drug assessment summary of Dupixent in atopic dermatitis
Figure 7: The author’s drug assessment summary of Dupixent in atopic dermatitis

List of Tables
Table 1: Dupixent drug profile
Table 2: Dupixent Phase III data in asthma
Table 3: Dupixent Phase III trials in asthma
Table 4: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Dupixent drug profile
Table 50: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Regeneron
  • Sanofi
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll